All Preferred Holders Demand $52 Million Redemption Lifecore Cannot Yet Pay
Distressed
Company Background
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) based in Chaska, Minnesota, specializing in sterile injectable pharmaceuticals and hyaluronic acid manufacturing. It operates roughly 248,000 square feet of production and laboratory space and employs approximately 400 people. Revenue for the fiscal year ended May 25, 2025 was $128.9 million, and guidance for calendar year 2026 calls for $120-$125 million, reflecting a temporary step-down driven by a lost customer, excess HA inventory pre-built by its largest customer, and a delayed commercial launch.
The balance sheet is heavily encumbered. As of March 31, 2026, Lifecore carried $142.1 million in related-party debt — a term loan from Alcon Research, LLC maturing May 2029 — most of which accrues paid-in-kind interest, meaning the balance grows over time. Related-party interest expense alone was $6.9 million in Q1 2026. A $29.7 million derivative liability tied to that same facility sits alongside it. Total liabilities of $204.7 million exceed total assets of $225.5 million when the preferred stock is included as a mezzanine obligation, leaving stockholders in a deficit of $28.4 million as of March 31, 2026.
The operating business has been improving, however. Adjusted EBITDA for the seven-month transition period through December 31, 2025 was $13.1 million, up sharply from $2.6 million in the comparable prior period. Q1 2026 generated $4.7 million in operating cash flow, and the company signed three new commercial programs during the quarter. The capital structure, not the operating trajectory, is what now defines the company's near-term situation.
What Was Disclosed
Every holder of Lifecore's Series A Redeemable Convertible Preferred Stock submitted redemption notices between June 29 and June 30, 2026 — the first days on which redemption was permitted under the terms of the instrument. All 49,263 shares outstanding were tendered simultaneously, triggering a single, undivided cash obligation. The redemption price is $1,000 per share plus accrued and unpaid dividends; as of June 30, 2026, accrued dividends totaled $0.9 million and the total liquidation value was approximately $50.2 million. With dividends accruing on additional shares issued as paid-in-kind distributions, the total amount required to complete the redemption on December 28, 2026 — exactly 180 days from the notice date — is approximately $52.1 million. Any portion unpaid after that date accrues interest at 1% per month.
As of March 31, 2026, Lifecore had $38.1 million in total liquidity: $20.8 million in cash and cash equivalents and $17.3 million in available capacity under its revolving credit facility. That liquidity figure is not directly comparable to the $52.1 million obligation, because Lifecore's credit agreements with its lenders expressly prohibit the company from making the redemption payment without first obtaining lender consent. Management says it has been pursuing that consent and continues to do so.
The company is evaluating "a range of strategic alternatives to facilitate the redemptions, including use of cash on hand, potential debt or equity financing transactions, and/or other possible strategic transactions." Management adds that it intends to pursue alternatives it believes will "improve its capital structure for what it expects to be its next phase of growth." The board says it "remains committed to maximizing value for the Company's stockholders."
Why It Matters
This was not a surprise. In the March 2026 earnings release, Lifecore explicitly stated that its financial guidance and outlook "does not contemplate that Lifecore will use its cash resources or raise additional financing in 2026 or in the near-term to (i) fund the redemption of the Series A Redeemable Preferred Stock." Management knew the redemption window opened June 29, 2026 and had already signaled to investors that addressing it would require a separate process outside normal operating cash flow. What the June 30 filing adds is that every single preferred holder exercised simultaneously on the first available day — a unified move that removes any question of whether or when the obligation would be triggered and locks in December 28 as a hard deadline.
The lender whose consent is required is Alcon Research, LLC, the holder of the $142.1 million related-party term loan. Alcon is also a major customer: related-party revenues — substantially Alcon-driven — represented roughly 42% of Lifecore's total revenues in the seven-month transition period ended December 31, 2025. Getting lender consent means negotiating with a party that is simultaneously Lifecore's largest creditor and one of its most significant customers, and whose term loan doesn't mature until May 2029. That dual relationship could facilitate or complicate the outcome, but the filing does not disclose any terms of ongoing negotiations.
On the positive side, the operating cash flow position is materially better than GAAP losses suggest. Q1 2026 generated $4.7 million from operations, and capital expenditures have fallen sharply to $1.1 million as the company's $90 million capacity buildout winds down. Management is guiding to $20.5-$25 million in Adjusted EBITDA for full-year 2026. The operating business is not the problem. What must be resolved before December 28 is a capital structure question: how to satisfy $52.1 million in cash demands using a combination of available liquidity, lender consent, and whatever new financing or strategic transaction can be arranged in roughly six months.